#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16212	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2578	777.9	0	.	n	.	0	C751T	SNP	751	751	C	1190	1190	T	1009	T,C,G	771,235,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16212	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2578	777.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1889	1889	T	1069	T,C,G	1062,4,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16212	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2578	777.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1623	1623	C	1095	C,A	1094,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16212	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2578	777.9	0	HET	.	.	.	A69G	.	69	69	A	508	508	A	1013	A,G	536,476	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27886	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3991	871.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1856	1856	A	1175	A,G,T,C	1169,3,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27886	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3991	871.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2490	2490	C	925	C,A	924,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27886	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3991	871.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2564	2564	A	868	A,C	866,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27886	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3991	871.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3116	3116	C	988	C	988	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2404	folP	852	852	99.88	folP.l15.c4.ctg.1	1873	159.5	0	.	p	.	0	E151K	NONSYN	451	453	GAA	930	932	AAA	240;239;240	A;A,G;A	240;238,1;240	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2404	folP	852	852	99.88	folP.l15.c4.ctg.1	1873	159.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1161	1163	AGC	233;233;232	A,G;G;C	232,1;233;232	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5424	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3799	177.9	1	SNP	p	S91F	0	.	.	271	273	TCC	758	760	TCC	206;205;202	T,G,C;C,A;C	204,1,1;204,1;202	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5424	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3799	177.9	1	SNP	p	D95G	0	.	.	283	285	GAC	770	772	GAC	197;197;197	G,T;A,C;C	196,1;196,1;197	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5424	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3799	177.9	1	SNP	p	D95N	0	.	.	283	285	GAC	770	772	GAC	197;197;197	G,T;A,C;C	196,1;196,1;197	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	2116	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1740	151.6	1	SNP	p	G45D	0	.	.	133	135	GGC	674	676	GGC	244;247;243	G;G;C	244;247;243	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1204	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1338	112.2	0	.	n	.	0	A197.	DEL	197	197	A	750	750	A	222	A	222	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5336	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3587	185.7	1	SNP	p	D86N	0	.	.	256	258	GAC	903	905	GAC	246;244;244	G;A,G;C	246;243,1;243	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5336	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3587	185.7	1	SNP	p	S87R	0	.	.	259	261	AGT	906	908	AGT	246;243;241	A,C;G,A;T	245,1;242,1;241	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5336	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3587	185.7	1	SNP	p	S87I	0	.	.	259	261	AGT	906	908	AGT	246;243;241	A,C;G,A;T	245,1;242,1;241	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5336	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3587	185.7	1	SNP	p	S87W	0	.	.	259	261	AGT	906	908	AGT	246;243;241	A,C;G,A;T	245,1;242,1;241	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5336	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3587	185.7	1	SNP	p	S88P	0	.	.	262	264	TCC	909	911	TCC	241;242;241	T,G;C;C	240,1;242;241	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4506	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3126	179.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1752	1754	GGC	251;249;246	G,C;G,A;C	250,1;248,1;246	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1496	1498	GCA	250;250;249	G;C;A,C	250;250;248,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1499	1501	ATC	252;250;253	A,T;T,G,C;C,T,A	250,2;248,1,1;251,1,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1511	1513	GTG	263;265;264	G,T;T;G,A	262,1;265;263,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1511	1513	GTG	263;265;264	G,T;T;G,A	262,1;265;263,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2015	2017	ACC	261;261;261	A;C,T;C	260;259,1;260	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2069	2071	GCG	249;246;247	G,T;C;G	247,2;246;247	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2069	2071	GCG	249;246;247	G,T;C;G	247,2;246;247	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2192	2194	GGC	227;227;225	G;G;C	227;227;225	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2201	2203	GGC	225;225;228	G;G;C,A	225;225;227,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4468	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2891	192.7	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2219	2221	CTG	226;226;225	C,A;T;G,C	224,1;225;223,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6212	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3609	214.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1856	1858	CCG	263;261;261	C,G;C,T,G;G	261,2;259,1,1;261	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2430	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2206	137.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	742	742	C	193	C	193	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	V258L	NONSYN	772	774	GTA	13	15	TTA	21;22;25	T;T;A	21;22;25	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	58	60	CAT	59;59;59	C;A;T	59;59;59	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	D274S	NONSYN	820	822	GAT	61	63	AGT	59;59;59	A;G;T	59;59;59	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	70	72	TAC	59;59;59	T;A;C	59;59;59	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	R307A	NONSYN	919	921	AGA	160	162	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	172	174	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	E312D	NONSYN	934	936	GAA	175	177	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	F314I	NONSYN	940	942	TTC	181	183	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	A316S	NONSYN	946	948	GCG	187	189	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	V318A	NONSYN	952	954	GTC	193	195	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	G319S	NONSYN	955	957	GGC	196	198	AGC	3;3;3	A;G;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	G320A	NONSYN	958	960	GGT	199	201	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	314	porB1a	984	222	90.54	porB1a.l15.c30.ctg.1	375	29.5	0	.	p	.	0	G322V	NONSYN	964	966	GGT	205	207	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3430	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1835	231.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	636	638	GAA	312;312;315	G,T;A,T;A	311,1;311,1;315	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3430	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1835	231.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	924	926	GAT	296;300;302	G,T;A,C;T,G,A	295,1;299,1;300,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3430	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1835	231.7	0	.	p	.	0	M141I	NONSYN	421	423	ATG	945	947	ATA	293;293;293	A;T,G;A,C	293;292,1;292,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3430	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1835	231.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1047	1049	TCA	290;289;292	T;C;A	290;289;292	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3430	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1835	231.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1176	1178	GTC	314;311;311	G,T;TCCCC,TCCC;C	313,1;298,1;311	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3430	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1835	231.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1506	1508	GCA	270;272;273	G,T;C,A;A,G	269,1;271,1;272,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3430	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1835	231.7	1	SNP	p	G120K	1	.	.	358	360	AAG	882	884	AAG	274;278;277	A,T,C;A;G	272,1,1;278;277	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3430	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1835	231.7	1	SNP	p	D121N	0	.	.	361	363	GAC	885	887	GAC	278;276;271	G,A;A;C	277,1;276;271	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3430	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1835	231.7	1	SNP	p	A121D	1	.	.	361	363	GAC	885	887	GAC	278;276;271	G,A;A;C	277,1;276;271	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11260	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5318	264.1	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2221	2223	AAT	309;308;305	A,C;A;T	308,1;308;305	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1796	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1321	169.2	1	SNP	p	V57M	1	.	.	169	171	ATG	725	727	ATG	324;325;324	A,C;T;G,A	323,1;325;323,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
